BACKGROUND: Nitric oxide (NO) is a candidate treatment for acute ischaemic stroke, however published studies in experimental stroke have given conflicting results. METHODS: We performed a systematic review of published controlled studies of L-arginine (the precursor for NO) and NO donors in experimental stroke. Data were analysed using the Cochrane Collaboration Review Manager software. Standardised mean difference (SMD) and 95% confidence intervals (95% CI) were calculated. RESULTS: Altogether, 25 studies(s) were identified. L-Arginine and NO donors reduced total cerebral infarct volume in permanent (SMD -1.21, 95% CI -1.69 to -0.73, p < 0.01, s = 10) and transient models of ischaemia (SMD -0.78, 95% CI -1.21 to -0.35, p < 0.01, s = 7). Drug administration increased cortical CBF in permanent (SMD +0.86, 95% CI 0.52-1.21, p < 0.01, s = 8) but not transient models (SMD +0.34, 95% CI -0.02 to 0.70, p = 0.07, s = 4). CONCLUSIONS: Administration of NO in experimental stroke reduces stroke lesion volume in permanent and transient models. This may be mediated, in part, by increased cerebral perfusion in permanent models. These data support clinical trials in stroke patients, although the presence of a narrow therapeutic time window may be a limiting factor.
BACKGROUND: Nitric oxide (NO) is a candidate treatment for acute ischaemic stroke, however published studies in experimental stroke have given conflicting results. METHODS: We performed a systematic review of published controlled studies of L-arginine (the precursor for NO) and NO donors in experimental stroke. Data were analysed using the Cochrane Collaboration Review Manager software. Standardised mean difference (SMD) and 95% confidence intervals (95% CI) were calculated. RESULTS: Altogether, 25 studies(s) were identified. L-Arginine and NO donors reduced total cerebral infarct volume in permanent (SMD -1.21, 95% CI -1.69 to -0.73, p < 0.01, s = 10) and transient models of ischaemia (SMD -0.78, 95% CI -1.21 to -0.35, p < 0.01, s = 7). Drug administration increased cortical CBF in permanent (SMD +0.86, 95% CI 0.52-1.21, p < 0.01, s = 8) but not transient models (SMD +0.34, 95% CI -0.02 to 0.70, p = 0.07, s = 4). CONCLUSIONS: Administration of NO in experimental stroke reduces stroke lesion volume in permanent and transient models. This may be mediated, in part, by increased cerebral perfusion in permanent models. These data support clinical trials in stroke patients, although the presence of a narrow therapeutic time window may be a limiting factor.
Authors: George W J Harston; Brad A Sutherland; James Kennedy; Alastair M Buchan Journal: J Cereb Blood Flow Metab Date: 2010-08-25 Impact factor: 6.200
Authors: Juraj Culman; Toni Jacob; Sven O Schuster; Kjell Brolund-Spaether; Leonie Brolund; Ingolf Cascorbi; Yi Zhao; Peter Gohlke Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2017-07-02 Impact factor: 3.000
Authors: Dmitriy N Atochin; Izumi Yuzawa; Qian Li; Kristen M Rauwerdink; Rajeev Malhotra; Junlei Chang; Peter Brouckaert; Cenk Ayata; Michael A Moskowitz; Kenneth D Bloch; Paul L Huang; Emmanuel S Buys Journal: Stroke Date: 2010-07-01 Impact factor: 7.914
Authors: Emily S Sena; H Bart van der Worp; Philip M W Bath; David W Howells; Malcolm R Macleod Journal: PLoS Biol Date: 2010-03-30 Impact factor: 8.029
Authors: H Bart van der Worp; David W Howells; Emily S Sena; Michelle J Porritt; Sarah Rewell; Victoria O'Collins; Malcolm R Macleod Journal: PLoS Med Date: 2010-03-30 Impact factor: 11.069
Authors: Anton Pekcec; Kazim Yigitkanli; Joo Eun Jung; Stefanie Pallast; Changhong Xing; Alexander Antipenko; Maria Minchenko; Dimitar B Nikolov; Theodore R Holman; Eng H Lo; Klaus van Leyen Journal: FASEB J Date: 2012-10-15 Impact factor: 5.191